Moderna, Through Valera, Its Infectious Disease Venture, Announces Initial Grant Of Up To $20 Million To Advance mRNA-Based Antibody Combination To Help Prevent HIV Infection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced a partnership with the Bill & Melinda Gates Foundation to advance the development of a novel, affordable combination of mRNA-based antibody therapeutics to help prevent human immunodeficiency virus (HIV) infection. The development efforts will be led by Valera, Moderna’s infectious disease-focused venture.